Phase 2 study of efficacy and safety of fosaprepitant in patients with solid tumor receiving highly emetogenic chemotherapy
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2018
Price : $35 *
At a glance
- Drugs Fosaprepitant (Primary) ; Dexamethasone; Granisetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 01 Jun 2018 Results published in the Medicine
- 09 Mar 2018 Status changed from active, no longer recruiting to completed.
- 08 May 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.